Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.61 |
| ▸ | POLG | P54098 | 1/20 | 0.42 |
| ▸ | DCK | P27707 | 15/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9066867 | 1.00 | ALB (0.61) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL7119054 | 1.00 | ALB (0.61) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL5608119 | 1.00 | ALB (0.61) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL9066905 | 1.00 | ALB (0.61) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL5607740 | 1.00 | ALB (0.61) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL12150303 | 0.85 | ALB (0.44) | ALBPOLGCACNA1FLMNAMAPT | |
| SCHEMBL14032177 | 0.85 | ALB (0.44) | ALBPOLGCACNA1FLMNAMAPT | |
| SCHEMBL27527424 | 0.82 | ALB (0.69) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL20735176 | 0.82 | ALB (0.54) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL10015802 | 0.81 | ALB (0.46) | ALBPOLGDCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171039-A1 | COMBINATIONS AND USES AND TREATMENTS | VIIV HEALTHCARE COMPANY | 2020-06-04 | — | — | US | disclosed |
| WO-2019030626-A1 | COMBINATIONS AND USES AND TREATMENTS THEREOF | VIIV HEALTHCARE COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171039-A1 | COMBINATIONS AND USES AND TREATMENTS | TYMP, DCTD, TPMT | ALB 2941/4885POLG 182/4885DCK 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.